Description
Composition- Glimepiride 2 mg + Metformin 500 mg + Voglibose 0.2 mg
Mode of Action- Enhances insulin release, reduces hepatic glucose production and delays intestinal carbohydrate absorption.
USPs- Triple pathway control; effective in postprandial hyperglycemia; improves overall glycemic outcomes.
Prescribing Specialties- Diabetologist, Internal Medicine
